{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:51:18Z","timestamp":1791881478573,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.12.068","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:59:17Z","timestamp":1766563157000},"page":"1206-1212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates in adjuvant and neoadjuvant therapies for resectable cutaneous melanoma"],"prefix":"10.1016","volume":"94","author":[{"given":"Matthew J.","family":"Hadfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Muzumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.12.068_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.068_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jaad.2025.12.068_bib3","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jaad.2025.12.068_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.068_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.068_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/1346-8138.17086","article-title":"Current surgical management for melanoma","volume":"51","author":"Koizumi","year":"2024","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.068_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jaad.2025.12.068_bib8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.068_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.jaad.2025.12.068_bib10","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.068_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose onterferon alfa-2b for resected high-risk melanoma: North American intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.068_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaad.2025.12.068_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.06.041","article-title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","volume":"173","author":"Larkin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2025.12.068_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2025.12.068_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006947","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0","volume":"11","author":"Pavlick","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.068_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.068_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jaad.2025.12.068_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.068_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40364-024-00671-0","article-title":"Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements","volume":"12","author":"Mart\u00ednez-P\u00e9rez","year":"2024","journal-title":"Biomark Res"},{"issue":"13","key":"10.1016\/j.jaad.2025.12.068_bib20","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7934","key":"10.1016\/j.jaad.2025.12.068_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.068_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.068_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jaad.2025.12.068_bib24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2025.12.068_bib25","doi-asserted-by":"crossref","first-page":"TPS9614","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9614","article-title":"A phase 1\/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis","volume":"42","author":"Zarka","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.068_bib26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u22641 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.12.068_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.003","article-title":"Adjuvant therapy for stage II melanoma: the need for further studies","volume":"189","author":"Lee","year":"2023","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.jaad.2025.12.068_bib28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.068_bib29","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"6892","key":"10.1016\/j.jaad.2025.12.068_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jaad.2025.12.068_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.068_bib32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","article-title":"Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600-mutant tumors","volume":"21","author":"Adashek","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.jaad.2025.12.068_bib33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.068_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/CMR.0000000000000888","article-title":"Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study","volume":"33","author":"Manzano","year":"2023","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2025.12.068_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113561","article-title":"Efficacy and safety of \u201cSecond Adjuvant\u201d therapy with BRAF\/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy","volume":"199","author":"Taylor","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2025.12.068_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102290","article-title":"Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study","volume":"65","author":"Bai","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"22","key":"10.1016\/j.jaad.2025.12.068_bib37","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.068_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1186\/s12885-022-09896-4","article-title":"Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial","volume":"22","author":"Rohaan","year":"2022","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.068_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a National Observational Cohort Study of 25 720 patients with stage IA to IV melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2026.04.030","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000}},{"DOI":"10.1016\/j.jaad.2026.04.030","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:25:29Z","timestamp":1791879929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225034504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225034504"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.068","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in adjuvant and neoadjuvant therapies for resectable cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}